Brief: Memphasys Expects To Receive Feedback From FDA In Early 2023 For Felix System
24/10/2022 24:18
Oct 24 (Reuters) - Memphasys Ltd MEM.AX :
* EXPECTS TO RECEIVE FEEDBACK FROM FDA IN EARLY 2023 FOR
FELIX
SYSTEM
Source text for Eikon: ID:nASX2bVg7j
Further company coverage: MEM.AX
Recent news on Memphasys
See all newsBrief: Memphasys Receives A$3.5 Million From Peters Investments
Brief: Memphasys Says Potential Expedited FDA Pathway To US IVF Market
Brief: Memphasys Secures 3-Year Felix Agreement With Invido For A$674,000 Minimum Purchases
Australia's Memphasys soars on signing exclusive commercialisation agreement with NOVIVITAE
Brief: Memphasys Says Vietnamese Registration For Felix System Has Been Achieved In August 2026